Dr. Sanjay Singh is the Chief Executive Officer, Gennova Biopharmaceuticals Limited, a subsidiary of Emcure Pharmaceuticals. He has been associated with Gennova since 2006.
At Gennova, his scientific expertise has led to several innovations to treat life-threatening diseases and Dr. Singh has been at the fore-front for developing India’s first mRNA vaccine for COVID-19.
Prior to joining Gennova, he worked with the National Institute of Health (NIH), USA where he headed the Antigen Research Section. He has won numerous awards from the US Department of Human and Health Services, some of which include ‘Special Act or Service Award’ in 2005 and ‘Staff Recognition Award, NIAID/NIH’ in 2004.
Dr. Singh completed his graduation and post-graduation in Science (Biochemistry) from the Lucknow University and is a Ph.D. in Biochemistry from the Central Drug Research Institute, Lucknow.